Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Deproteinized asparagus polysaccharide is a bioactive carbohydrate extracted from *Asparagus officinalis* that has undergone protein removal, typically via the Sevag method. It demonstrates significant anticancer activity, particularly against hepatocellular carcinoma (HCC), by inducing G2/M phase cell cycle arrest and promoting apoptosis. Mechanistically, it modulates the expression of apoptosis-related proteins, including the upregulation of Bax and caspase-3 and the downregulation of Bcl-2. Additionally, it has been shown to act as a chemosensitizer, enhancing the tumoricidal efficacy of chemotherapeutic agents like mitomycin in both in vitro and in vivo models.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on deproteinized asparagus polysaccharide.